Comparative Pharmacology
Head-to-head clinical analysis: BROMPHERIL versus PROMETHACON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHERIL versus PROMETHACON.
BROMPHERIL vs PROMETHACON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brompheril is a mu-opioid receptor agonist with additional sigma-1 receptor antagonism, producing analgesic effects and modulating neuropathic pain.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), antiemetic, sedative, and anticholinergic properties. It inhibits central and peripheral H1 receptors, blocks dopamine D2 receptors in the chemoreceptor trigger zone, and has weak alpha-adrenergic blockade.
In adults, the usual dose is 1-2 mg/kg intravenously every 4-6 hours as needed. Alternatively, 5 mg can be administered intramuscularly or subcutaneously every 4 hours.
25-50 mg intramuscularly or intravenously every 4-6 hours as needed. Maximum intravenous rate: 25 mg/minute. Maximum daily dose: 150 mg.
None Documented
None Documented
Terminal half-life 2.5-4 hours; prolonged in renal impairment (up to 12 hours in severe cases).
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 10-14 hours in hepatic impairment
Primarily renal (60-70% as unchanged drug); 15-20% fecal via biliary elimination; minor metabolic clearance.
Renal (80%) as inactive metabolites, 20% fecal via bile
Category C
Category C
Antihistamine
Antihistamine